Navigation Links
Repligen Reports First Quarter Fiscal Year 2010 Financial Results
Date:8/6/2009

to $63,961,000 as of March 31, 2009.

"We are pleased to have advanced our pipeline programs this quarter, and we expect to receive pivotal data from both our Phase 3 pancreatic imaging and Phase 2b bipolar depression studies in 2010," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "Our financial resources will allow us to continue to pursue our goal to build a sustainable biopharmaceutical company by developing innovative products that have the potential to markedly improve patients' lives."

Corporate Update

RG1068 for Imaging of the Pancreas

We are currently enrolling patients in a Phase 3 clinical trial of RG1068, synthetic human secretin, designed to assess the ability of RG1068 in combination with magnetic resonance imaging (MRI) to improve the detection of pancreatic duct abnormalities compared to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the diagnosis and treatment of diseases such as acute and chronic pancreatitis. This study is being conducted at approximately 30 clinical sites within the U.S. and Canada and will enroll approximately 225 patients. We have made steady progress on enrollment and plan to complete this trial by the end of the year. The FDA has granted this program Fast Track Designation, a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need. There are more than 300,000 MRI procedures conducted in the U.S. and Europe each year that could benefit from the use of RG1068.

RG2417 for Bipolar Disorder

We are currently enrolling a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depressi
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
(Date:7/10/2014)... Ceres, Inc . (Nasdaq: CERE ), an ... for the three months ended May 31, 2014 and ... reported that the company and its customers have made ... Brazil, which concluded in June, despite dry and hot ... part of the growing season. Yields of several of ...
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2
... CALGARY, Oct. 26 /PRNewswire-FirstCall/ - SemBioSys Genetics ... of therapeutic,proteins for metabolic and cardiovascular diseases, ... scientific poster and abstract at the Seventh ... by the Diabetes,Technology Society. The poster will ...
... ECG services, RESEARCH TRIANGLE PARK, N.C., Oct. ... H. Cabell, M.D., MHS,FACC, an expert cardiologist and ... group in Global Clinical Development Services,(CDS). In addition ... for Quintiles ECG Services. Cabell comes to ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) management will be presenting at ... Rodman & Renshaw 9th Annual Healthcare Conference being ... Hotel in New York City. Schaefer ... will provide an overview of the company on Tuesday, ...
Cached Biology Technology:SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting 2Expert Cardiologist Joins Quintiles Medical Group 2Pharmasset to Present at Three Investor Conferences in November 2007 2
(Date:7/10/2014)... 2014 Fingerprint Cards, (FPC,s) ... win (DW). An Asian OEM has selected FPC1021 for a ... in August 2014.   FPC is proud to ... a planned date for start of mass production in August ... SEK 5M, for delivery in the first half of July. ...
(Date:7/10/2014)... An international team ... step of photosynthesis in action for the first time. The ... used the world,s most powerful X-ray flashlight at the US ... molecular complex called photosystem II as it splits water into ... earth,s atmosphere. The researchers report their results in the scientific ...
(Date:7/10/2014)... Marshall Institute for Interdisciplinary Research (MIIR) and the ... today announced they will be partnering with an ... , Under the agreement with Shanghai-based HD Biosciences ... costs and risks of discovery and development of ... any intellectual property and commercialization rights to products ...
Breaking Biology News(10 mins):FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2Scientists watch photosynthesis in action 2Scientists watch photosynthesis in action 3Marshall University to partner with international company in drug development venture 2
... A team of scientists studying the effects of ... its research published in the February issue of the ... said the study,s lead investigator. The study quantified ... the use of electron-beam irradiation. "The purpose of ...
... have led to the discovery of a new species of ... la Muerte". The discovery was made thanks to molecular data ... the overall knowledge of plant lice (one of the most ... 20%. The study was published in the open access journal ...
... DNA sequencing to detect genetic mutations can aid ... Current methods of testing DNA samples, Sanger sequencing ... difficult or impossible to interpret. Scientists at the ... free software program, Pyromaker, that can more accurately identify ...
Cached Biology News:Study shows electron-beam irradiation reduces virus-related health risk in lettuce, spinach 2Study shows electron-beam irradiation reduces virus-related health risk in lettuce, spinach 3A new species of bamboo-feeding plant lice found in Costa Rica 2New virtual tool may provide more accurate diagnosis of genetic mutations 2
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... Analysis of large numbers of samples may be ... which requires minimum operator attention. System ... software and interface CE 4900. The elegant, ... in Windows XP and Windows 98 and 2000., ...
Biology Products: